Other

EU approves merger of Pfizer off-patent unit and Mylan

The European Commission on Wednesday authorised a merger of US drug giant Pfizer's off-patent business unit with the pharmaceutical company Mylan to create a global powerhouse for lower-cost medicines.

Medical economics

Brand drug discount cards increase private insurer costs by 46%

Discount cards for brand-name drugs provided to patients increased private insurer costs by 46% and varied in their impact on out-of-pocket payments by patients, found new research in CMAJ (Canadian Medical Association Journal).

page 1 from 4